Steroid shield: new hope to prevent HIV treatment complications
NCT ID NCT07565623
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This study tests whether a short course of the steroid prednisolone can prevent a serious immune overreaction called IRIS in people with advanced HIV who are starting antiretroviral therapy. About 262 participants with low immune cell counts and active infections will be randomly assigned to receive either prednisolone or no extra treatment. The goal is to see if the steroid reduces the risk of IRIS over 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV - HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.